Pathobiology research at EORTC aims to identify and validate biomarkers across cancer types that can be used to develop new or more targeted treatments.
EORTC has implemented a cross group policy for biobanking
EORTC research has resulted in the clinical qualification of uPA/PAI-1 as a class 1 level-of-evidence biomarkers for the prognosis of node-negative breast cancer patients. These biomarkers were subsequently recommended by national and international guidelines.
It has also contributed to the validation of gene-expression profiles and to the discovery of mechanisms of breast cancer metastasis leading to more personalised treatment for this cancer.